Christopher Vann has been named chief operating officer of Autolus Ltd, a portfolio company of the Syncona investment group which is developing engineered T cell immunotherapies. Dr Vann joins Autolus from Roche where he oversaw the lifecycle management of oncology products.
Also named to new positions at Autolus are Matthias Alder as chief business officer, Muhammad Al-Hajj as head of translational sciences and Nushmia Khokhar as head of clinical development. Mr Alder joins from Sucampo Pharmaceuticals Inc. He has also held corporate development and legal roles at Cytos Biotechnology AG and Micromet Inc. Dr Al-Hajj joins from the Burnham Institute in the US and Dr Khokhar from Janssen Oncology where she was global clinical leader for the multiple myeloma drug daratumumab.
Autolus announced the appointments on 18 July 2017.
Copyright 2017 Evernow Publishing Ltd